Educational Development: STORM and AlidaBio Partner to Enhance RNA Modification Analysis in Cancer

### Advancements in RNA Modification Analysis: A Strategic Partnership

STORM Therapeutics Ltd. (STORM) and Alida Biosciences Inc. (AlidaBio) forge a strategic collaboration aimed at enhancing the understanding of RNA modifications in cancer treatment. Announced on January 8, 2026, this partnership combines STORM’s pioneering METTL3 inhibitor, STC-15, with AlidaBio’s advanced next-generation sequencing (NGS) platforms, EpiPlex® and EpiScout®. This collaboration seeks to investigate the impact of METTL3 inhibition on N6-methyladenosine (m6A) RNA modifications in clinical samples from cancer patients. By analyzing these modifications, the companies aim to correlate changes in m6A dynamics with clinical responses to treatment, thereby enhancing the development of personalized cancer therapies.

The collaboration is particularly significant as STC-15 is the first small molecule drug targeting an RNA-modifying enzyme, currently undergoing Phase 1/2 clinical trials. This innovative approach not only focuses on the mechanistic understanding of RNA regulation but also aims to identify baseline m6A characteristics that could potentially predict sensitivity to METTL3 inhibition. Dr. Eric Martin, Chief Development Officer of STORM, emphasizes AlidaBio’s expertise as critical for deciphering transcript-specific m6A changes, which could lead to more effective cancer treatment strategies. Through this collaboration, both companies aim to validate m6A-regulated genes and specific cell types influenced by METTL3 inhibition, paving the way for the discovery of epitranscriptomic biomarkers that can refine patient selection for upcoming clinical trials.

Dr. Gudrun Stengel, CEO of AlidaBio, expresses confidence that their advanced sequencing platforms will facilitate comprehensive analysis of m6A biology in patient samples. This capability is vital for evaluating the clinical efficacy of STC-15 and may significantly contribute to the broader field of epitranscriptomics in drug development. As the research progresses, both companies anticipate that their findings will advance the understanding of RNA modifications and their implications for improving patient outcomes in cancer therapy. This collaboration not only highlights the innovative research methodologies being employed but also underscores the increasing relevance of RNA modifications in developing targeted therapies.

In addition to this partnership, the industry continues to witness advancements in RNA therapeutic development. A recent webinar hosted by Rockland Immunochemicals will delve into universal detection strategies for identifying chemical modifications in oligonucleotide therapeutics, focusing on their implications for drug localization and action. This event, aimed at professionals in the RNA therapeutic field, underscores the ongoing commitment to refining drug development processes through advanced analytical techniques.

Moreover, Muna Therapeutics recently received a $1 million grant from the Alzheimer’s Association to support its clinical trials involving the TREM2 receptor, highlighting the emphasis on innovative therapeutic approaches in the biotechnology sector. This trend reflects a broader movement towards utilizing cutting-edge research to address urgent healthcare needs through advanced therapeutic modalities.